Point solutions for areas like behavioral health, family planning and more have risen in popularity in recent years, experts said. But as employers deal with point solution fatigue, healthcare navigation companies are proving beneficial.
Don't miss your opportunity to experience the premier networking event in healthcare. Join us May 22-24, 2023 at the Ritz Carlton in Chicago and get access to exclusive networking opportunities, mingle with investors and cutting edge startups, Ask CIOs, and so much more.
Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDS).
The final rule calls for stricter audits on Medicare Advantage plans. AHIP president and CEO Matt Eyles referred to the rule as "unlawful and fatally flawed."
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
Season one focusing on chronic disease management kicks off with a conversation with Stephanie Tilenius, CEO of VIda Health that aims to treat both the mind and the body.
Less than 20% of behavioral healthcare providers collect data on how patients are progressing with their treatment. To buck this trend, Two Chairs is rolling out "mental health snapshots," which are consistent summaries of patients' well-being designed to offer real-time insight to both clinicians and clients.
Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to experience shortages of these viral vectors.
This eBook highlights how contract research organizations are collaborating with technology developers, the role that digital therapeutics could play in clinical trials, how companies are thinking about clinical trial diversity and the challenges in using real-world evidence to replicate clinical trials.
No comments:
Post a Comment